PPARG and nasal cavity polyp: A study from 2019 explored the role of HMGB1 in driving EMT in eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP) whilst also highlighting the therapeutic potential of peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists [58].